Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
01 Novembro 2023 - 9:30AM
Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines, today announced the appointment of
James Bristol, Ph.D., to its Board of Directors.
“Dr. Bristol is a seasoned biopharmaceutical executive who has
excelled as a corporate partner, board member, and strategic and
technical advisor within our industry,” said Matt Angel, Ph.D.,
Chief Executive Officer and President of Eterna. “We are thrilled
to have him join our Board as we continue our mission of supporting
the development of next-generation therapies using mRNA cell
engineering.”
Dr. Bristol added, “Eterna’s mRNA cell engineering platform is a
stand out in the industry and I look forward to working with the
leadership team and Board to fully realize its potential.”
Dr. Bristol’s career in research & development and drug
discovery has spanned more than 30 years. Since his retirement from
Pfizer in 2007, he has spent the subsequent 16 years as a
consultant, actively engaged in various Boards of Directors,
Scientific Advisory Board and advisory roles in the
biopharmaceutical industry, including Chairman of the Board of
Directors of Deciphera Pharmaceuticals, Lead Independent Director
of Erasca, and Senior Advisor to Frazier Life Sciences.
Prior to his retirement, Dr. Bristol was Senior Vice President,
Worldwide Drug Discovery Research at Pfizer, overseeing discovery
collaborations and managing a large team of scientists across
multiple company sites in the U.S., U.K., and Japan who produced an
industry-leading number of drug development candidates across 11
broadly defined therapeutic areas. Before that, he worked at
Parke-Davis for 20 years, where he held positions of increasing
responsibility in Chemistry and Drug Discovery and participated in
collaboration oversight committees. Early in his career, Dr.
Bristol was a Principal Scientist at Schering-Plough, leading the
gastrointestinal research program. His drug discovery research has
resulted in numerous publications, abstracts, and patents. Dr.
Bristol holds a Ph.D. in Organic Chemistry from the University of
New Hampshire and a B.S. in Chemistry from Bates College.
About Eterna Therapeutics Inc.Eterna
Therapeutics is a life science company committed to realizing the
potential of mRNA cell engineering to provide patients with
transformational new medicines. Eterna has in-licensed a portfolio
of over 130 patents covering key mRNA cell engineering
technologies, including technologies for mRNA cell reprogramming,
mRNA gene editing, the NoveSlice™ and UltraSlice™ gene-editing
proteins, and the ToRNAdo™ mRNA delivery system from Factor
Bioscience. NoveSlice™, UltraSlice™, and ToRNAdo™ are trademarks of
Factor Bioscience. For more information, please
visit www.eternatx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which are intended
to be covered by the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are any statements that are not statements of historical
fact and may be identified by terminology such as “believe,”
“could,” “estimate,” “anticipate,” “expect,” “plan,” “possible,”
“potential,” “project,” “will” or other similar words and the
negatives of such words. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those stated or implied in any
forward-looking statement as a result of various factors,
including, but not limited to, uncertainties related to: (i) the
evolution of Eterna’s business model into a platform company
focused on mRNA, induced pluripotent stem (iPS) cell and gene
editing technologies; (ii) Eterna’s ability to successfully,
cost-effectively and efficiently develop its technology and
products; (iii) Eterna’s ability to successfully commence clinical
trials of any products on a timely basis or at all; (iv) Eterna’s
ability to successfully fund and manage the growth of its
development activities; and (v) Eterna’s ability to obtain
regulatory approvals of its products for commercialization. You
should not rely upon forward-looking statements as predictions of
future events. The forward-looking statements made in this
communication speak only as of the date on which they were made,
and Eterna does not undertake any obligation to update the
forward-looking statements contained herein to reflect events that
occur or circumstances that exist after the date hereof, except as
required by applicable law. Factors that may cause Eterna’s actual
results to differ from those expressed or implied in
forward-looking statements contained in this press release are more
fully disclosed in Eterna’s periodic public filings with the U.S.
Securities and Exchange Commission, particularly under the heading
“Risk Factors” in Eterna’s Annual Report on Form 10-K for the year
ended December 31, 2022, as well as under similar headings in
Eterna’s subsequently filed Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K.
Investor Relations
Contact:investors@eternatx.com
Media Contact:EternaPR@westwicke.com
Eterna Therapeutics (NASDAQ:ERNA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eterna Therapeutics (NASDAQ:ERNA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024